This Phil operator President, Thank Inc. our XXXX. for clinical Dr. are of and financial pharmaceuticals. Today, our provide is third Veru you specialty you Greco, me development joining And morning. urology CAO we the of as pipeline biopharmaceutical of the oncology is and medicines Vice good and the well you prostate focusing as am joining fiscal Mitchell company on update novel Steiner. and Veru quarter products and highlights and commercialization CFO our call. the cancer on Michele will on Greenberg, Chairman, President Executive Thank and I CEO for Legal. a urology drug
advanced citrate also Lupron, drugs for Zoladex. their supportive By the hot estrogen in XXX,XXX to means cancer of testosterone symptoms drugs bone density, are essentially developed loss for the their Firmagon treatment an order in have therapy, stop lowering are therapy prostate levels same works includes no with hot estrogen cancer. of we FDA deprivation novel known U.S. Currently, for women treatment to fractures therapy to indication. of hormone low levels, the low approved estrogen is VERU-XXX care. since men In zuclomiphene oral Andro spread andro as flashes cancer. loss the like and estrogen treat from and and cancer as these castrate are by prostate cancer of for who in Eligard, Let's and deprivation are men Normal testosterone being too. for libido. men of bone the therapy agent Low of androgen estrogenic therapy evaluated progression levels testosterone. flashes, also known deprivation then as well. in the we being estrogen men Zuclomiphene, deprivation start on converting by make prostate prostate the important men, into deficiency very levels lowering postmenopausal levels essentially there these are medicines prostate Over and men Androgen mineral
of history unwanted to use stop XX% side to therapy. the flashes flashes is or the component therapy Because estrogen XX% of deprivation which to the was men XX% hot of In effects treatment about solution severe side find known Up fact, want hot common until individual debilitating related sweating, flashes have Many resolve. daily eight are men side in Clomid, these episodic these to one to uncontrollable originally effects flashes moderate intermittently approved XXXX, most years even and and activities of the the therapy. andro to heat, zuclomiphene there because clinical be related drug. by deprivation flashes is experienced FDA may these effect. of a his Zuclomiphene hot the by lot which to called andro even hot deprivation of up could flashes a caused stop hot drug deficiency Hot of manage are a the the sensation later. cause andro
known of As have cis-isomers own for which clomiphene our efficacy, is dose animal We steroidal are zuclomiphene the for steroidal FDA a work flashes being the estrogenic nonsteroidal that for estrogens without have to scientific the from studies. do thus know used agent in an confirmed activity estrogens we approved understanding this indication potential off of safety and of risks. hot established but not or treatment an label are literature
used given not so to weak agent, potential deprivation by it of a reasons safety to able main In men. the hot widely be safety One profile. potent estrogens the the contrast, serious steroidal nonsteroidal estrogenic caused for flashes androgen will because of reduce zuclomiphene a with different therapy is when are concerns is
is prostate safety U.S. by based we safety the available the evidence hypogonadism. the indication well literature hormone zuclomiphene should it as safety fact, against Thus, In direct indirect have zuclomiphene, a used therapy drugs different flashes infertility has be over nonsteroidal a men make year as cancer profile. data Furthermore, existing well-tolerated. to appears such for is databases one up in as similar clinical or a XX,XXX hot estrogenic scientific should agent, and effective suggest the and each on and different and be that that FDA from label the of in men being two have safety as Clomid, zuclomiphene off on
based the treatment are efficacy reasons, a therapy appropriate prostate we by for caused profile. on and these as hormone For in hot the to advanced zuclomiphene flashes men with safety dose evaluating formally cancer ascertain
FDA we June to clinical FDA light a the now on zuclomiphene, and the Phase has green with the officially given for X us development IND testing. XXXX enter filed of As
The miligrams, for dose a XX the of the conducted It to a should patient placebo-controlled, trial three expected Phase arm period study to XX first sites blinded, primary of The Phase by evaluate moderate study clinical approximately U.S. weeks. only to in study. doses trial a month. and study flashes XXX It the is X will over study. X in frequency plan XX different to The is arm that weeks XX treatment be miligrams XX compared clinical short placebo. XXX the with men total be be XX this per is four We from the as endpoint rolled randomized, finding hot severe in a is maintained the clinical men and reduction of to oral is daily zuclomiphene, in miligrams, in weeks baseline four
protection which the of is Zuclomiphene enclomiphene the be any intellectual approved an should never for drug. old enclomiphene two XXXX. and of made though We report final worldwide. expect zuclomiphene, first without has Phase noted, clinical even drugs, to Clomid, its half pure indication up form data have It strong in been property for zuclomiphene X in is we
XXXX. patent We of an in have been granted zuclomiphene expiration a office the date use for by with method U.S. patent
As I annual mentioned there U.S. on in alone. XXX,XXX potentially hormone the cancer earlier, over prostate men $XXX an therapies million for this market estimated an making
prostate metastatic a and VERU-XXX an we intravenously cancer hormonal oral our castrate so anti-tubulin prostate against cancer. activity next-generation second advanced and medicine for treatment prostate like drug demonstrated resistant prostate cancer, therapy been are given that the has developing against far as cancer. oral of therapy like androgen significant metastatic and enzalutamide and novel abiraterone anti-tubulin Next, novel resistant alpha anti-tumor either sensitive By targets is background, indeed blocking novel, the tubulin metastatic or prostate and VERU-XXX, effective androgen way deprivation cancer therapies. metastatic taxane only VERU-XXX have anti-tubulin beta animal In of prostate cancer, subunits hormone resistant and resistant models, castration of microtubules. agent metastatic castration advanced
enzalutamide. are who metastatic have who resistant unmet need in have also planning cancer to to or which and Xtandi which developed for VERU-XXX We medical is become initially resistant to who prostate failed respond men have abiraterone, Zytiga castration the to, is
be FDA the will filing to also blocking June for American reported represents not pancreatic anti-tubulin clinical drugs Society a and as reported needs prostate other fill that be of study. formulated end cancer and XXXX. and markets just executing anti-tumor additional We with preclinical will anticipate In activity advanced bioequivalence against opportunity having that for of this XXXX, cancer the label the then developed label sites that breast, provides of therapy and late meeting to open but Meeting, a pharmaceutical Clinical under VERU-XXX's medical safety treated We Veru being human or urology is will today. specialty in its XXXX Oncology conduct in results early could sensitive by the oral intravenously with only Phase evidence study further negative efficacy an study. that a trial we the growth highly closely revenue instead other showing anti-tubulin and currently clinical and not efficacy Hopkins of so given require development multibillion and will work regarded several part this of An by VERU-XXX have having cancer, dollar triple also androgen the quarter data Johns other year. to we near-term any IND on every we novel evidence tumor oral also plan efficacy and treated that initiating part strategy VERU-XXX The may showing important types and studies, chemotherapies. open preclinical new that an urology against pre-IND but safety patient clinical agent of require unmet Annual resistant XB/X be cancers. This by with expect as means types VERU-XXX are receive resistant prostate an for and early ovarian the taxane soon
bioequivalency drugs to successful in multiple plan in several file urology commercialize the NDAs of completion near-term. Following we and studies,
pharmaceuticals. to NDAs update of the expect our months. on will XX we briefly you next four fact, for urology In three now drugs specialty I the file over progress
suspension slow formulation DRS, amount Flomax is which two First, to we with gets given levels label granules rapidly release XX% drug and that products, food when absorbed two release an has a new empty Flomax. new more effect, drugs a blood branded up of formulations the in proprietary to of drug means These which oral in results XX% the XR the administration Tamsulosin according tamsulosin drug concerns greater for extended capsules. stomach. have higher address Tamsulosin of granule on
POTS, or unwanted a after Flomax meal. hypotension must fainting, the prevent effects be dizziness, XX FDA to precaution a orthostatic minutes given that As states label like side
food and to based on both its Our a advantage tamsulosin and current provides we conducted. that administration already granules a novel have appears formulation in capsules food and granule not studies compared compliance bioequivalency clinical of have Flomax This lack release for effect slow drug major to generics. two a effect
launch bioequivalency The planned XXXX. We for XXXX. is in data expect final
clinical quickly prostate. ingredients formulation. advantage NDA tadalafil medicine final dysfunction It added anticipate filing pill of also tablet Cialis, of This in one Our fixed an treats prostate also which having We third tablet prostate proprietary and progressive tadalafil a contains men active erectile enlarged it urology the combination which treatment formulation pill, active and drug that XXXX. combination of late prevents development of BPH, in for with size tadalafil/finasteride approved an formulation, finasteride in shrinks miligrams, has of tablet, is proprietary approved data male the is tadalafil-finasteride the of the miligrams the bioequivalency the urinary combination for the enlarged for ingredients. who the Proscar, new erectile of shrinking X as X combination present male treat its symptoms growth X while an finasteride dysfunction Hence, BPH. to call BPH clinical X we formulation, symptoms miligrams miligrams and
and DRG. ingredient fourth bladder, active Solifenacin of called urge urgency, is urology in frequency development a popular clinical formulation the Solifenacin, in It's is delayed incontinence drug both of drug men in overactive granule for and an release VESIcare, proprietary treatment a which Our women.
tablets. swallowed must any women MX and chewed. condition overactive are be and granule common difficulty muscarinic men cannot or for have or bladder formulations crushed whole not who the no Solifenacin of for receptor available are be for have swallow of the selective or tablets There antagonists
in delivery Solifenacin and expect granules women release NDA Tamsulosin proprietary men in release for technology bioequivalence for and slow filing the as treatment of platform DRS utilizes formulation the granules final DRG Solifenacin DRG we Our bladder same have data an overactive slow XXXX. that and we
activities great clinical year paid our we is this the In quantities public leading the advancing FCX see, is channel drugs. have global agencies by nongovernmental the U.S. these regulatory progress Condom produced by our FCX company governments the both in and is can made revenue clarity sector pipeline markets. obtaining bulk health in this multiple has from and part health by and world's condom. development the of the public health We public where and of from you commercial the PREBOOST. products, the donor global female division year FCX The for distribution. health Female purchased revenue female for This sector, As
their impact shortly. Furthermore, and past who and largest place quarters two this year, since sold, this of will XX% fiscal did in this XX For of fiscal QX we fiscal first which this is quarter felt to of orders second great not fiscal had our October quarter XXXX. of past procurement the division, We XXXX. Pharmaceuticals normal reported acquisition million details units quarter Aspen from our with Michele customers, the Park due the a for year and South increase an of cycles. provide Brazil we year financial Africa, best this
part, Looking now million XXX forward, a expected year award any Africa South years know per is funding we in unit to award. tender XX for totaling that million needs day units support to three tender our
are will We we African results amount that tender receive the looking the confident Africa new and are announcing from awards we tender to South of forward South substantial soon. a
a expect XX of the tender portion also Brazil be units XXXX. million to We in awarded of
the Finally, has U.S. corner. the turned FCX business
We increase U.S. even in QX. is sales. in have prescription seen in the part and better-than-expected is be saw price fiscal in expected reason the sales which to growth QX better we unit nonprescription fiscal in This
will the creation resources additional FCX FCX clinical and As value continue and Michele? to I novel care pharmaceuticals. our has of CFO prostate to value call business CAO mentioned shareholder the objective through before, commercialization specialty the and highlights. cancer the medicines discuss to partially and I now turn of development The proprietary is to cancer provide we business. main urology prostate Michele supportive fund of increase which the financial well as will and over as Greco, product
